Plural Hetero Atoms In The Tricyclo Ring System Patents (Class 514/291)
  • Patent number: 9292660
    Abstract: Provided herein are methods and systems of molecular profiling of diseases, such as cancer. In some embodiments, the molecular profiling can be used to identify treatments for a disease, such as treatments that were not initially identified as a treatment for the disease or not expected to be a treatment for a particular disease.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: March 22, 2016
    Assignee: Caris MPI, Inc.
    Inventors: Daniel D. Von Hoff, David M. Loesch, Arlet Alarcon, Robert J. Penny, Alan Wright, Matthew J. McGinniss, Ryan P. Bender, Traci Pawlowski
  • Patent number: 9248319
    Abstract: The present invention relates to functional composite particles for the oral care sector, more particularly for toothpastes and mouthwashes, which are charged with active ingredients which ensure a long-term antimicrobial or antibacterial effect in the oral cavity and hence reduce the formation of plaque and halitosis. The invention further relates to a process for producing these composite particles and also to their use for producing oral hygiene articles.
    Type: Grant
    Filed: August 6, 2010
    Date of Patent: February 2, 2016
    Assignee: Evonik Degussa
    Inventors: Wojciech Pisula, Stephanie Schäffer, Juri Tschernjaew, Arnold Storeck, Rainer Hahn
  • Patent number: 9242979
    Abstract: The present invention relates to methods for synthesizing tiotropium bromide following the scheme: Using the above scheme, tiotropium bromide (compound 6C) is obtained under mild conditions and with high yields.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: January 26, 2016
    Inventor: Mahmut Bilgic
  • Patent number: 9211278
    Abstract: Composition and method for preventing and/or treating dementia and ameliorating memory impairment and/or improving memory, comprising one or more arylnaphthalene lignan derivatives, namely Justicidin A, 5-methoxyjusticidin A, Chinensinaphthol, and a pharmaceutically-acceptable salt thereof, as active ingredient.
    Type: Grant
    Filed: September 25, 2013
    Date of Patent: December 15, 2015
    Assignees: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY, CSIR
    Inventors: Hyun Ok Yang, Sung-Kwon Chung, Hak Cheol Kwon, Jin Wook Cha, Young-Joo Kim, Gerda Fouche, Rudzani Nthambeleni, Dashnie Naidoo, Jeremiah Senabe, Vinesh Jaichand Maharaj, Eric Khorombi, Jungyeob Ham, Joon Ki Kim
  • Patent number: 9205080
    Abstract: A method of treating or preventing keratin hyperproliferation skin disorders is set forth. The method includes the administration of an mTOR inhibitor to a subject afflicted with the hyperproliferation disorder. The mTOR inhibitor can be administered to the subject via any means known in the art including oral, topical, and transdermal administration.
    Type: Grant
    Filed: November 16, 2007
    Date of Patent: December 8, 2015
    Assignee: Transderm, Inc.
    Inventors: Roger Louis Kaspar, Robyn Patricia Hickerson
  • Patent number: 9193687
    Abstract: The present disclosure relates to new DNA-directed alkylating agents and water-soluble N-mustard agents with improved chemical stability and anti-tumor therapeutic efficacy.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: November 24, 2015
    Assignee: Academia Sinica
    Inventors: Tsann-Long Su, Ting-Chao Chou, Te-Chuang Lee
  • Patent number: 9187454
    Abstract: The invention provides novel inhibitors of cancer stem cells as well as cancer stem cell pathway kinase and other related kinases, pharmaceutical compositions and uses thereof in the treatment of cancer or a related disorder in a mammal, and methods of making such compounds and compositions.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: November 17, 2015
    Assignee: Boston Biomedical, Inc.
    Inventors: Chiang Jia Li, Ji-Feng Liu, Wei Li, Amanda Gibeau, Harry Rogoff
  • Patent number: 9169269
    Abstract: This invention relates to new water-soluble solid pharmaceutical inclusion complexes and their aqueous solutions for oral, ophthalmic, topical or parenteral use containing a macrolide and certain cyclodextrins. More particularly the invention relates to new water-soluble solid pharmaceutical inclusion complexes and their solutions in aqueous solvents, said compositions containing a) as an active ingredient a macrolide such as Rapamycin, Pimecrolimus, Temsirolimus, Everolimus or Tacrolimus in an amorphous form and optionally in the form of their polymorphic hydrates or solvates e.g. solvates formed with acetone or ethanol. b) a large surface cyclodextrin, such as gamma cyclodextrin—whereby the weight ratio of said macrolide to said cyclodextrin ranges between 1:111 and 1:333.
    Type: Grant
    Filed: June 29, 2011
    Date of Patent: October 27, 2015
    Assignee: EUTICALS SPA
    Inventors: Alberto Mangia, Paride Grisenti, Elisa Verza, Shahrzad Reza Elahi, Riccardo Monti
  • Patent number: 9168246
    Abstract: The present invention relates to a method of suppressing organ rejection in a patient receiving an organ transplant by initiating oral treatment with a once-daily extended release tacrolimus dosage form, for example, at an initial dose of from about 0.15 to about 0.20 mg/kg/day within 24 or 48 hours following transplantation. The once-daily extended release tacrolimus dosage form (i) provides low fluctuation and/or swing of tacrolimus, (ii) provides a significantly lower Cmax than an immediate release formulation of tacrolimus while providing the same or greater area under the curve (AUC), (iii) releases the tacrolimus substantially in the colon and/or the lower ileum, (iv) releases at most 63.5% of the tacrolimus in the dosage form at the 12 hour time point, or (v) any combination of any of the foregoing.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: October 27, 2015
    Assignee: VELOXIS PHARMACEUTICAL A/S
    Inventor: William J. Polvino
  • Patent number: 9149470
    Abstract: The present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the general formula:
    Type: Grant
    Filed: November 22, 2011
    Date of Patent: October 6, 2015
    Assignee: ELIXIR MEDICAL CORPORATION
    Inventors: John Yan, Xiaoxia Zheng, Vinayak D. Bhat
  • Patent number: 9085575
    Abstract: The present invention relates to compounds of following general formula (I): and to the pharmaceutically acceptable salts of same, the tautomers of same, the stereoisomers or mixture of stereoisomers in any proportions of same, such as a mixture of enantiomers, notably a racemic mixture, as well as to methods for preparing same and uses of same, notably as an antineoplastic agent.
    Type: Grant
    Filed: April 12, 2012
    Date of Patent: July 21, 2015
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: Rémi Rabot, Karim Bedjeguelal, El Bachir Kaloun, Philippe Schmitt, Nicolas Rahier, Patrice Mayer, Emmanuel Fournier
  • Patent number: 9060928
    Abstract: A tacrolimus injection preparation comprising tacrolimus, polyoxyethylene castor oil (35), and non-aqueous solvent is disclosed. Preferably the weight ratio of polyoxyethylene castor oil (35) to tacrolimus in the injection preparation is 10-20:1. The injection preparation significantly decreased the clinical risk.
    Type: Grant
    Filed: April 2, 2010
    Date of Patent: June 23, 2015
    Assignee: FUZHOU HARVESTER PHARMACEUTICAL R&D CO., LTD.
    Inventor: Na Zhang
  • Publication number: 20150148318
    Abstract: A method of inhibiting the growth of cancer cells is disclosed in which cancer cells that contain an enhanced amount relative to non-cancerous cells of one or more of phosphorylated mTOR, Akt1, ERK2 and serine2152-phosphorylated filamin A are contacted with an FLNA-binding effective amount of a compound or a pharmaceutically acceptable salt thereof that binds to the pentapeptide of filamin A (FLNA) of SEQ ID NO: 1 and exhibits at least about 60 percent of the FITC-labeled naloxone binding amount when present at a 10 ?M concentration and using unlabeled naloxone as the control inhibitor at the same concentration. A compound that binds to the FLNA pentapeptide preferably also contains at least four of the six pharmacophores of FIGS. 19-24.
    Type: Application
    Filed: September 26, 2014
    Publication date: May 28, 2015
    Inventors: Hoau-Yan Wang, Lindsay Burns Barbier
  • Publication number: 20150147402
    Abstract: The present invention provides an implantable device having a coating including a slow dissolving polymer or material and the methods of making and using the same.
    Type: Application
    Filed: November 17, 2014
    Publication date: May 28, 2015
    Inventors: O. Mikael Trollsas, Michael H. Ngo, David J. Sherman, Syed F.A. Hossainy
  • Publication number: 20150148292
    Abstract: The disclosure relates to compounds and compositions for bone formation, fracture treatment, bone grafting, bone fusion, cartilage maintenance and repair, and methods related thereto.
    Type: Application
    Filed: July 8, 2013
    Publication date: May 28, 2015
    Inventors: Scott D Boden, Sreedhara Sangadala
  • Publication number: 20150148294
    Abstract: A method for treating endocrine tumors by administration of an mTOR inhibitor, optionally in combination with another drug.
    Type: Application
    Filed: January 29, 2015
    Publication date: May 28, 2015
    Applicant: Novartis AG
    Inventors: Peter Wayne Marks, David Lebwohl
  • Publication number: 20150140099
    Abstract: A pharmaceutical composition for inhalation comprising aclidinium in the form of a dry powder of a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable dry powder carrier, providing a delivered dose of aclidinium equivalent to about 322 micrograms aclidinium free base.
    Type: Application
    Filed: May 30, 2013
    Publication date: May 21, 2015
    Inventors: Sandrine Allain Ruiz, Beatriz Seoane Nunez, Gonzalo De Miguel Serra
  • Publication number: 20150141491
    Abstract: The present invention relates to novel methods for the prevention, treatment and diagnosis of Alzheimer's disease. In addition, the invention relates to methods for assessing an individual's susceptibility or pre-disposition to Alzheimer's disease. The methods of the present invention involve the use of therapeutic targets and diagnostic and/or predictive markers within the mTOR signalling pathway. The methods also involve screening subjects for genetic polymorphisms associated with rapamycin-sensitive genes.
    Type: Application
    Filed: July 11, 2013
    Publication date: May 21, 2015
    Inventor: Zsuzsanna Nagy
  • Publication number: 20150140071
    Abstract: The disclosed molecules are inhibitors of Bcr-Abl and Src kinases. The molecules are cytotoxic to Gleevec resistant cells. Inhibitors of Bcr-Abl and Src kinases are used in the treatment of Chronic Myelogenous Leukemia among other diseases.
    Type: Application
    Filed: November 11, 2014
    Publication date: May 21, 2015
    Inventor: Ayyappan K. Rajasekaran
  • Publication number: 20150140133
    Abstract: A system is described for long-term controlled release delivery of a drug or a therapeutic agent. According to the invention, one or more drugs or therapeutic agents contained in microspheres are mixed with a temperature sensitive hydrogel which is then introduced directly to the desired situs of the drug or therapeutic agent. The temperature sensitive hydrogel may also contain a drug or a therapeutic agent, for example, a pain relieving drug, for a short-term controlled release. The temperature sensitive hydrogel is in liquid state at room temperature, but upon injection, shortly becomes gelatinous. This system is particularly suitable for treatment of diseases, disorders, or conditions, for example, tumors, discogenic back pain, or arthritis, warranting localized administration of a drug or a therapeutic agent. In addition, the specification provides a method for production of a drug- or therapeutic agent-containing microspheres.
    Type: Application
    Filed: December 4, 2014
    Publication date: May 21, 2015
    Inventor: Tae-Hong Lim
  • Publication number: 20150133487
    Abstract: This invention relates to tritoqualine for use in the treatment of cystic fibrosis or any one of its complications. The invention also relates to the method for the treatment of cystic fibrosis or any one of its complications by administering tritoqualine. The invention can be used to improve the condition of individuals with cystic fibrosis.
    Type: Application
    Filed: April 19, 2013
    Publication date: May 14, 2015
    Inventor: Dominique Costantini
  • Publication number: 20150132260
    Abstract: The present invention relates to the use of the measure of anelloviral load for the determination of immunosuppression. More precisely, the present invention provides a method for characterizing the immunosuppressed or non-immunosuppressed status of a subject, comprising the steps of determining the anelloviral load from a biological sample of the said subject, and determining from the said comparison the immunosuppressed or non-immunosuppressed status. The determination of the immunosuppressed status of the subject can then be used to design or adapt a therapeutic treatment.
    Type: Application
    Filed: April 19, 2013
    Publication date: May 14, 2015
    Inventors: Marc Eloit, Justine Cheval, Charles Hebert, Marc Lecuit
  • Publication number: 20150133378
    Abstract: A method for identifying a kidney transplant recipient at an increased risk of developing interstitial fibrosis or tubular atrophy which comprises obtaining a post-transplant urine sample from the kidney transplant recipient; measuring the level of clusterin in the urine sample; comparing the level of clusterin in the patient sample to the level of clusterin in a control sample from the urine of a non-fibrotic kidney transplant recipient; diagnosing a kidney transplant recipient with a clusterin level that is significantly higher than the clusterin level in the control as being at an increased risk of developing interstitial fibrosis or tubular atrophy.
    Type: Application
    Filed: April 17, 2013
    Publication date: May 14, 2015
    Inventors: Barbara Murphy, Philip J. O'Connell
  • Publication number: 20150134048
    Abstract: The present invention is directed to polymeric materials comprising biodegradable, dioxanone-based copolymers and implantable devices (e.g., drug-delivery stents) formed of such materials. The polymeric materials can also contain at least one additional biocompatible moiety, at least one non-fouling moiety, at least one biobeneficial material, at least one bioactive agent, or a combination thereof. The polymeric materials are designed to improve the mechanical, physical and biological properties of implantable devices formed thereof.
    Type: Application
    Filed: January 22, 2015
    Publication date: May 14, 2015
    Inventor: Ni Ding
  • Publication number: 20150134047
    Abstract: Provided herein is a device comprising: a. stent; b. a plurality of layers on said stent framework to form said device; wherein at least one of said layers comprises a bioabsorbable polymer and at least one of said layers comprises one or more active agents; wherein at least part of the active agent is in crystalline form.
    Type: Application
    Filed: May 21, 2013
    Publication date: May 14, 2015
    Inventors: James B. McClain, Charles Douglas Taylor
  • Publication number: 20150132397
    Abstract: The invention relates to the use of inhibitors of the enzyme mTOR kinase (mammalian target of rapamycin) in the treatment of neuro-oncologic diseases, in particular tuberous sclerosis, neurodegenerative diseases, in particular Alzheimer's disease, and neuroinflammatory diseases, in particular multiple sclerosis and primary progressive aphasia, via intrathecal, or preferably intraventricular, administration of said inhibitors.
    Type: Application
    Filed: May 10, 2013
    Publication date: May 14, 2015
    Inventor: Diego DOLCETTA
  • Patent number: 9029544
    Abstract: The present invention relates to compounds defined by formula I wherein the variables R1-R8 are defined as in the description, possessing valuable pharmacological activity. Particularly, the compounds are inhibitors of cholesterol ester transfer protein (CETP) and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme.
    Type: Grant
    Filed: February 17, 2011
    Date of Patent: May 12, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Holger Wagner, Daniela Berta, Klaus Fuchs, Riccardo Giovannini, Dieter Wolfgang Hamprecht, Ingo Konetzki, Ruediger Streicher, Thomas Trieselmann
  • Publication number: 20150126580
    Abstract: Methods for diagnosing and treating cancer associated with an oncogenic Kras mutation in a subject are provided.
    Type: Application
    Filed: December 19, 2012
    Publication date: May 7, 2015
    Inventors: Ronald A. DePinho, Lewis Cantley, Alec C. Kimmelman, Haoqiang Ying, Costas A. Lyssiotis
  • Publication number: 20150125510
    Abstract: A method of modifying the surface of a medical device to release a drug in a controlled way by providing a barrier layer on the surface of one or more drug coatings. The barrier layer consists of modified drug material converted to a barrier layer by irradiation by an accelerated neutral beam derived from an accelerated gas cluster ion beam. Also medical devices formed thereby.
    Type: Application
    Filed: August 22, 2012
    Publication date: May 7, 2015
    Inventors: Sean R. Kirkpatrick, Richard C. Svrluga, Stephen M. Blinn
  • Patent number: 9023371
    Abstract: Medical device are provided for delivering a therapeutic agent to a tissue. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent and an additive. In certain embodiments, the additive has a hydrophilic part and a drug affinity part, wherein the drug affinity part is at least one of a hydrophobic part, a part that has an affinity to the therapeutic agent by hydrogen bonding, and a part that has an affinity to the therapeutic agent by van der Waals interactions. In embodiments, the additive is water-soluble. In further embodiments, the additive is at least one of a surfactant and a chemical compound, and the chemical compound has a molecular weight of from 80 to 750 or has more than four hydroxyl groups.
    Type: Grant
    Filed: March 18, 2013
    Date of Patent: May 5, 2015
    Assignee: Lutonix, Inc.
    Inventor: Lixiao Wang
  • Publication number: 20150112116
    Abstract: Provided herein are methods comprising providing a tyrosine derivative and a solid particulate material (and, optionally, melanin) and applying force to said tyrosine derivative and said solid particulate material for a time and under conditions effective to impregnate at least one of said tyrosine derivative and said solid particulate material with the other of said tyrosine derivative and said solid particulate material. The invention also provides compositions comprising at least one of a tyrosine derivative impregnated with a solid particulate material and a solid particulate material impregnated with a tyrosine derivative.
    Type: Application
    Filed: October 24, 2013
    Publication date: April 23, 2015
    Inventor: STEVEN HOFFMAN
  • Publication number: 20150111891
    Abstract: The invention provides compounds and salts thereof as d herein. The invention also provides pharmaceutical compositions comprising a compound disclosed herein, processes for preparing compounds disclosed herein, intermediates useful for preparing compounds disclosed herein and therapeutic methods for treating an HIV infection, treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS or ARC symptoms in a mammal using compounds disclosed herein.
    Type: Application
    Filed: January 3, 2013
    Publication date: April 23, 2015
    Applicant: Gilead Sciences, Inc.
    Inventors: Kerim Babaoglu, Gediminas Brizgys, Hongyan Guo, Paul Hrvatin, Eric Lansdon, John O. Link, Hongtao Liu, Ryan McFadden, Michael L. Mitchell, Yingmei Qi, Paul A. Roethle, Randall W. Vivian, Lianhong Xu, Hong Yang
  • Publication number: 20150112424
    Abstract: A method for depositing a coating comprising a polymer and at least two pharmaceutical agents on a substrate, comprising the following steps: providing a stent framework; depositing on said stent framework a first layer comprising a first pharmaceutical agent; depositing a second layer comprising a second pharmaceutical agent; Wherein said first and second pharmaceutical agents are selected from two different classes of pharmaceutical agents.
    Type: Application
    Filed: August 29, 2014
    Publication date: April 23, 2015
    Inventors: James DeYoung, Doug Taylor, Jim McClain, Clint Smoke, Mike Cole
  • Publication number: 20150110735
    Abstract: A centrifugal mixing device can include a shaft assembly that is operably coupled to a motor such that the motor rotates the shaft assembly about a first axis. The devices can further include a turret that is rotatably coupled to the shaft assembly such that the turret rotates about the first axis relative to the shaft assembly. The turret can include a first support, a first canister rotatably coupled to the first support such that the first canister rotates about a second axis, and a second canister rotatably coupled to the first support such that the second canister rotates about a third axis. The turret is configured to rotate about the first axis in a first rotational direction and each of the first and second canisters is configured to rotate about the second and third axes, respectively, in a second rotational direction that is opposite the first rotational direction.
    Type: Application
    Filed: October 22, 2013
    Publication date: April 23, 2015
    Inventor: Steven Hoffman
  • Patent number: 9011923
    Abstract: The present invention relates to suspension formulations, especially those for delivering a pharmaceutically active agent in aerosol form using a spray or aerosol device, such as a pressurized metered dose inhaler (pMDI). The formulations may be for pulmonary, nasal, buccal or topical administration, but are preferably for pulmonary inhalation.
    Type: Grant
    Filed: February 2, 2009
    Date of Patent: April 21, 2015
    Assignees: Innovata Biomed Limited, Vectura Limited
    Inventors: David Andrew Lewis, Christina Alexandra Keeble, Nicola Kim Whitfield, Tanya Church
  • Patent number: 9005161
    Abstract: The invention relates to a medical device for delivering a therapeutic agent to a tissue. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent, an antioxidant, and an additive. In certain embodiments, the additive has a hydrophilic part and a drug affinity part, wherein the drug affinity part is at least one of a hydrophobic part, a part that has an affinity to the therapeutic agent by hydrogen bonding, and a part that has an affinity to the therapeutic agent by van der Waals interactions. In some embodiments, the additive is a liquid. In other embodiments, the additive is at least one of a surfactant and a chemical compound, and the chemical compound has one or more hydroxyl, amino, carbonyl, carboxyl, acid, amide or ester groups.
    Type: Grant
    Filed: March 18, 2013
    Date of Patent: April 14, 2015
    Assignee: Lutonix, Inc.
    Inventor: Lixiao Wang
  • Patent number: 9006229
    Abstract: The invention provides compounds of formula I: or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS or ARC symptoms in a mammal using compounds of formula I.
    Type: Grant
    Filed: April 20, 2012
    Date of Patent: April 14, 2015
    Assignee: Gilead Sciences, Inc.
    Inventors: Michael L. Mitchell, Paul A. Roethle, Lianhong Xu, Hong Yang, Ryan McFadden, Kerim Babaoglu
  • Publication number: 20150098932
    Abstract: Compositions and methods are disclosed for treating vitiligo and promoting the formation of collagen.
    Type: Application
    Filed: December 16, 2014
    Publication date: April 9, 2015
    Inventor: Sarah Bacus
  • Publication number: 20150099765
    Abstract: Disclosed are muscarinic agonist compounds including oxadiazole derivatives, compositions and preparations thereof. Also disclosed are methods of synthesizing such oxadiazole compounds. Further disclosed are methods for treating a subject with said muscarinic agonists or a pharmaceutically suitable form thereof to enhance cognitive function.
    Type: Application
    Filed: October 6, 2014
    Publication date: April 9, 2015
    Inventors: Michael L. Hendrickson, Jeffrey C. Ockuly, Trevor M. Twose, Melinda L. Verdone, Brent D. Abraham, Richard R. Copp, James G. Farnham, Seth A. Hanson
  • Publication number: 20150098977
    Abstract: Implantable devices formed of or coated with a material that includes a polymer having a non-fouling acrylate or methacrylate polymer are provided. The implantable device can be used for treating or preventing a disorder such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, patent foramen ovale, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, or combinations thereof.
    Type: Application
    Filed: December 9, 2014
    Publication date: April 9, 2015
    Inventor: Stephen D. Pacetti
  • Patent number: 8999292
    Abstract: This invention relates to, in part, methods and compositions that are useful for the diagnosis, treatment, or prevention of a blinding eye disease, including in the discovery of drugs that are efficacious against these diseases. Diseases include, for example, age related macular degeneration and reticular pseudodrusen disease, and the methods described herein include, for example, the method named delayed near infrared analysis (DNIRA).
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: April 7, 2015
    Assignee: Translatum Medicus Inc.
    Inventor: Shelley Romayne Boyd
  • Patent number: 9000004
    Abstract: An ambroxol hydrochloride composition and a preparation method therefor. 0.1%-99.9% by mass of ambroxol hydrochloride and 99.9%-0.1% by mass of scopolamine serving as main ingredients and mannitol are added into water for injection; dissolve, then adjust to pH 5.0; add 0.1% of activated carbon with stirring; filter out the activated carbon, and then filter the liquid; send into a lyophilizer, cool to ?40° C., and hold the temperature for 2 hours; warm to ?5° C. to 0° C. slowly to lyophilize the liquid, heat to 35° C., and hold the temperature for 3 hours; take out of the lyophilizer to obtain a lyophilized powder injection containing ambroxol hydrochloride and scopolamine; crush the lyophilized powder injection under sterile conditions, and sieve to obtain sterile lyophilized powder containing ambroxol hydrochloride and scopolamine; and prepare various dosage forms by using the lyophilized powder as a raw material.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: April 7, 2015
    Assignee: Hainan Weikang Pharmaceutical (Qianshan) Co., Ltd.
    Inventors: Liuyi Wang, Jincan Wang
  • Patent number: 9000031
    Abstract: The present specification provides compositions comprising a thioxanthone-based autophagy inhibitor and/or a cancer therapeutic autophagy inducing compound, pharmaceutical kits comprising these compositions, and methods of treating cancer using such compounds, compositions and kits. Additionally, the present specification provides methods of treating cancer using a thioxanthone-based autophagy inhibitor and a radiotherapy.
    Type: Grant
    Filed: August 6, 2013
    Date of Patent: April 7, 2015
    Assignee: Spectrum Pharmaceuticals, Inc.
    Inventors: Steffan Nawrocki, Jennifer Carew, Guru Reddy
  • Publication number: 20150086600
    Abstract: A drug-delivering insertable medical device for treating a medical condition associated with a body lumen is disclosed. The drug-delivering insertable medical device includes an outer surface coated with two or more nano-carriers having two or more average diameters. A nano-carrier of the two or more nano-carriers has an average diameter suitable for penetrating one or more layers of two or more layers of the body lumen. The nano-carrier includes a drug surrounded by an encapsulating medium. The encapsulating medium includes one or more of a biological agent, a blood excipient, and a phospholipid.
    Type: Application
    Filed: July 15, 2014
    Publication date: March 26, 2015
    Applicant: ENVISION SCIENTIFIC PRIVATE LIMITED
    Inventors: MANISH DOSHI, PRAKASH SOJITRA, ALEXANDRE ABIZAID
  • Publication number: 20150087671
    Abstract: A drug delivery composition including a lipophilic agent or a biologic agent and a polymer wherein the lipophilic agent exhibits sustained release and wherein there is less than 35% agent release within the first hour of elution. A drug delivery composition including a lipophilic agent or a biologic agent and a polymer wherein the elution profile is substantially linear, and wherein there is less than 35% agent release within the first hour of elution. The lipophilic agent may be crystalline and the biologic agent may be in active form.
    Type: Application
    Filed: May 16, 2013
    Publication date: March 26, 2015
    Inventors: James B. McClain, Charles Douglas Taylor, Wenda C. Carlyle
  • Patent number: 8987295
    Abstract: The present invention is directed to substituted azoanthracene derivatives or pharmaceutically acceptable salts thereof that modulate the human GLP-1 receptor and that may be useful in the treatment of diseases, disorders, or conditions in which modulation of the human GLP-1 receptor is beneficial, such as diabetes mellitus type 2. The invention is also directed to pharmaceutical compositions comprising these compounds and to the use of these compounds and compositions in the treatment of such diseases, disorders, or conditions in which modulation of the human GLP-1 receptor is beneficial.
    Type: Grant
    Filed: December 6, 2012
    Date of Patent: March 24, 2015
    Assignee: TransTech Pharma, LLC
    Inventors: Adnan M. M. Mjalli, Christopher Behme, Daniel P. Christen, Devi Reddy Gohimukkula, Dharma Rao Polisetti, James C. Quada, Jr., Jennifer L. R. Freeman, Kalpathy Santhosh, Muralidhar Bondlela, Mustafa Guzel, Ravindra Reddy Yarragunta, Robert Carl Andrews, Stephen Thomas Davis, Thomas Scott Yokum
  • Publication number: 20150079177
    Abstract: The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents, or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime.
    Type: Application
    Filed: August 25, 2014
    Publication date: March 19, 2015
    Inventors: Neil P. DESAI, Patrick SOON-SHIONG, Tapas DE
  • Publication number: 20150079116
    Abstract: NK cell licensing predisposes patients to chronic inflammatory disease. Methods and kits to diagnose and treat chronic inflammatory disease based on genetic haplotype and cytokine profile are described herein.
    Type: Application
    Filed: April 11, 2013
    Publication date: March 19, 2015
    Inventors: Jonathan Braun, Lin Lin
  • Publication number: 20150079160
    Abstract: A drug-delivering medical device for delivering a drug to a target site in a human body is disclosed. The drug-delivering medical device may have a hydrophilic surface, with one or more portions of the hydrophilic surface coated with one or more nano-carriers bearing one or more drugs. Each nano-carrier may include a drug surrounded by an encapsulating medium. As the drug is surrounded by the encapsulating medium, the surface of each nano-carrier can be devoid of the respective drug. A non-implantable medical device coated with nano-carriers can deliver one or more drugs to a blood vessel, organ cavity, sac, capsule, lining, layer, coating, membrane, connective tissue, fluid surrounding an organ, and so forth.
    Type: Application
    Filed: August 12, 2014
    Publication date: March 19, 2015
    Applicant: CONCEPT MEDICAL RESEARCH PRIVATE LIMITED
    Inventors: MANISH DOSHI, Prakash Sojitra, Pedro A Lemos Neto
  • Publication number: 20150072975
    Abstract: The present invention relates to antibacterial compounds of formula I: wherein all variable substituents are defined as described herein, which are useful for the treatment of bacterial infections.
    Type: Application
    Filed: November 18, 2014
    Publication date: March 12, 2015
    Inventors: Berangere Gaucher, JR., Franck Hubert Danel, XiaoHu Tang, Tong Xie, Lin XU